Core Viewpoint - Hunan Fangsheng Pharmaceutical Co., Ltd. has received the Drug Registration Certificate for Loxoprofen Sodium Gel Patch, allowing for production and sales, which enhances its product line in orthopedic medications and competitive position in the market [1][4]. Group 1: Drug Registration and Details - The Drug Registration Certificate for Loxoprofen Sodium Gel Patch was approved by the National Medical Products Administration on January 23, 2026 [1]. - Loxoprofen Sodium Gel Patch is indicated for osteoarthritis, muscle pain, and swelling pain after injuries, with significant anti-inflammatory and analgesic effects [1]. - The active ingredient, Loxoprofen Sodium, is a non-steroidal anti-inflammatory drug (NSAID) that works by inhibiting prostaglandin synthesis [1]. Group 2: Market Situation - As of the announcement date, 15 companies in China have obtained the Drug Registration Certificate for Loxoprofen Sodium Gel Patch, including listed companies such as Jiutian Pharmaceutical, Darentang, and China Resources Sanjiu [3]. - According to Moen Pharmaceutical data, the total hospital sales of Loxoprofen Sodium Gel Patch reached 1.349 billion yuan in the first three quarters of 2025, with retail sales in physical pharmacies amounting to 142 million yuan in the first half of 2025 [3]. Group 3: Impact on the Company - The approval of Loxoprofen Sodium Gel Patch enriches the company's product line for orthopedic diseases and enhances its competitiveness in the market, potentially improving overall profitability [4]. - The company has invested a total of 7.0366 million yuan in the drug project, including research and development and technology transfer [2]. - The company emphasizes the importance of drug research and development, maintaining strict quality control in the drug development, manufacturing, and sales processes [4].

Core Viewpoint - Zhejiang Shapuaisi Pharmaceutical Co., Ltd. has received approval for the supplementary application of Diflunisal tablets, which enhances the company's product line and market competitiveness [1][5]. Group 1: Drug Approval Details - Drug Name: Diflunisal Tablets [2][3] - Dosage Form: Tablet [2][3] - Specifications: 0.25g and 0.5g [2][3] - Registration Category: Chemical Drug [2][3] - License Holder and Manufacturer: Zhejiang Shapuaisi Pharmaceutical Co., Ltd. [2][3] - Approval Conclusion: The drug has passed the consistency evaluation of generic drug quality and efficacy [1][2]. Group 2: R&D Investment - The cumulative R&D investment for the Diflunisal tablet project is approximately 7.1492 million RMB [4]. Group 3: Market Impact - The approval of Diflunisal tablets is expected to enrich the company's product line and enhance the market competitiveness of this product [5].

Core Viewpoint - The company has received a drug registration certificate for its product, Amlodipine Besylate Tablets, which is expected to enhance its product line and market competitiveness [1]. Group 1: Product Development - The company's subsidiary, Xinxiang Changle Pharmaceutical Co., Ltd., has been granted a drug registration certificate by the National Medical Products Administration for Amlodipine Besylate Tablets [1]. - The product is indicated for the treatment of primary hypertension in adults, with projected sales of approximately 58.73 million yuan in 2024 [1]. - The registration application for Amlodipine Besylate Tablets (40mg/80mg) was first submitted in August 2024 and has now been approved, signifying compliance with the consistency evaluation of generic drug quality and efficacy [1]. Group 2: Financial Investment - The research and development investment for Amlodipine Besylate Tablets has reached approximately 10.99 million yuan (unaudited) as of the announcement date [1]. - The company has obtained 10 production licenses for the product as of the announcement date [1]. Group 3: Market Impact - The acquisition of the drug registration certificate is expected to enrich the company's product line and enhance the competitiveness of its products in the market [1]. - The impact of this registration on the company's recent operating performance is not anticipated to be significant [1].

Core Viewpoint - The company has received approval from the National Medical Products Administration for the drug Pioglitazone Metformin Tablets (15mg/500mg), enhancing its diabetes medication product line and market competitiveness [1] Group 1: Product Approval - The Pioglitazone Metformin Tablets (15mg/500mg) have been approved as a Class 3 chemical drug, indicating it has passed the consistency evaluation for generic drug quality and efficacy [1] - This approval allows the company to expand its diabetes treatment offerings, which is expected to strengthen its position in the market [1] Group 2: Market Strategy - The company plans to actively prepare for the launch of the new product and aims to bring it to market as soon as possible [1] - There may be uncertainties affecting the production and sales of the new product, which the company will need to navigate [1]

Core Viewpoint - Zhejiang Xianju Pharmaceutical Co., Ltd. has successfully passed the consistency evaluation for the quality and efficacy of Nicardipine Hydrochloride Injection, which is expected to enhance the product's market competitiveness and accumulate experience for future evaluations [1][4]. Group 1: Drug Information - The drug Nicardipine Hydrochloride Injection is a calcium channel blocker primarily used for rapid blood pressure reduction and managing acute hypertension situations, such as during surgery or in emergency settings [3]. - The approved specifications for Nicardipine Hydrochloride Injection are 10ml:10mg (approval number H20258264) and 5ml:5mg (approval number H20258265), with the product adhering to the national drug registration standard YBH32372025 [3]. Group 2: Approval Details - The approval for the drug was granted based on the regulations outlined in the Drug Administration Law of the People's Republic of China and related announcements, allowing the addition of 5ml:5mg and 10ml:10mg specifications [2].

Core Viewpoint - Prolo Pharmaceutical's subsidiary, Zhejiang Prolo Jutai Pharmaceutical Co., Ltd., has received a drug registration certificate for Amoxicillin Clavulanate Potassium Tablets from the National Medical Products Administration, which is expected to enhance market competitiveness and sales potential in the Chinese hospital market [1] Group 1: Product and Market Information - The drug is indicated for the treatment of upper respiratory infections, lower respiratory infections, urinary system infections, skin and soft tissue infections, and oral infections [1] - The projected market size for the Chinese hospital market in 2024 is 760 million tablets, with a sales value of 620 million yuan [1] Group 2: R&D and Regulatory Aspects - Cumulative R&D investment for the drug has reached 10.8245 million yuan [1] - The drug is considered to have passed the consistency evaluation of generic drug quality and efficacy, qualifying it for participation in the national drug centralized procurement renewal [1]

Core Viewpoint - The announcement highlights that the company's wholly-owned subsidiary, Zhuhai United Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration of China for its injectable Cefoperazone Sodium and Sulbactam Sodium (2.0g), which has passed the consistency evaluation of generic drug quality and efficacy [1] Group 1: Product Approval and Specifications - The injectable Cefoperazone Sodium and Sulbactam Sodium is a third-generation cephalosporin antibiotic with broad-spectrum antibacterial activity, suitable for monotherapy or combination therapy [1] - It is indicated for the treatment of infections caused by sensitive bacteria, including respiratory, urinary, intra-abdominal, septicemia, meningitis, skin and soft tissue, bone and joint, and reproductive tract infections [1] Group 2: Market Position and Future Prospects - The product is listed as a Class B drug in the National Medical Insurance Directory (2024 edition), which may enhance its market accessibility [1] - The approval is expected to help the company strengthen its competitive position in the anti-infection field and contribute to greater returns for the company and its shareholders through ongoing product development and consistency evaluations [1]

Group 1 - The company has elected Mr. Zheng Fangwei as the employee director of the fifth board of directors, with a term starting from November 24, 2025 [1][3] - The election of the employee director complies with relevant laws and regulations, ensuring that the number of employee representatives does not exceed half of the total board members [1] Group 2 - The company's wholly-owned subsidiary, Shanghai Sitaili Pharmaceutical Co., Ltd., has received a drug registration certificate for Gadopentetate Dimeglumine Injection from the National Medical Products Administration [4][5] - The drug is classified as a Class 4 chemical drug and is primarily used for magnetic resonance imaging of various organs and tissues [5][7] - The total R&D investment for this drug has reached approximately 7.07 million yuan [6] - The market data indicates that the sales of Gadopentetate Dimeglumine Injection in Chinese public medical institutions are expected to exceed 700 million yuan in 2024 [8]

Core Insights - The article discusses the rapid growth and development of Nanjing Commer Biopharmaceutical Co., Ltd. (Commer Pharma), a Contract Research Organization (CRO) established in June 2020, which has expanded to over 500 employees and completed several hundred million yuan in financing [1][2] Group 1: Company Overview - Commer Pharma has been recognized as a "potential unicorn enterprise" in Jiangsu and has entered the "Future Star of Science and Technology" list in 2023 [1] - The company aims to provide comprehensive drug development services, addressing the inefficiencies in traditional CRO services that often involve single-step outsourcing [2][3] Group 2: Market Dynamics - The demand for innovative drug development is increasing due to healthcare cost control and centralized procurement policies, leading to a surge in outsourcing needs [3][6] - The global pharmaceutical industry is shifting towards China, creating a significant gap for CRO services that meet international regulatory standards [3][6] Group 3: Technological Capabilities - Commer Pharma has established nine specialized technology platforms, covering areas such as solid-state drug research and transdermal drug delivery systems, to create a full-service development loop from preclinical research to clinical trials [3][4] - The company employs a highly qualified team, with over 150 employees holding master's or doctoral degrees and more than 80% having over five years of experience in drug development [4] Group 4: Innovation and Problem Solving - Commer Pharma successfully addressed a complex challenge in developing a triple-combination drug for HIV, optimizing the formulation to reduce production costs by 10% while improving absorption rates [4][5] - The company emphasizes the need for innovative processes to enhance efficiency and reduce costs in drug development, particularly in the context of high standards for consistency evaluation [5] Group 5: Future Aspirations - Commer Pharma is constructing a GLP-compliant research headquarters to enhance its capabilities in non-clinical safety evaluations, aiming to support global multi-center clinical trials and facilitate market entry for clients in Europe and the U.S. [6][7] - The company aspires to become a globally competitive, one-stop innovative CRO platform, providing end-to-end solutions from target discovery to commercial production [7]

Core Viewpoint - The company has received approval for its cephalosporin product, marking a significant milestone in its market strategy and potential for growth [1] Group 1: Product Approval - The company's wholly-owned subsidiary, Zhejiang Pro Pharmaceutical Co., Ltd., has been granted a drug registration certificate for its cephalosporin dry suspension (1.5g; 3.0g) by the National Medical Products Administration [1] - This product is the first generic drug in China to be approved and deemed to have passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 2: Market Implications - The approval allows the product to qualify for participation in national medical insurance negotiations, which is expected to enhance its market sales and competitiveness [1] - The company may face uncertainties in production and sales due to potential changes in policies, regulations, and market conditions [1]